Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity
- PMID: 8136944
- DOI: 10.1097/00002371-199402000-00005
Production of interleukin-2 by EL4 tumor cells induces natural killer cell- and T-cell-mediated immunity
Abstract
Systemic administration of recombinant interleukin (rIL)-2 to cancer patients has met with limited clinical success since, despite significant antitumor effects, its use is associated with severe toxicity. Local production of IL-2 by IL-2 gene transfected tumor cells in murine model systems has been reported to induce specific immunity--devoid of toxicity--to the parental non-IL-2-producing tumor cells. We now report enhanced resistance in nonimmunized mice to murine EL4 thymoma cells, producing murine IL-2 following gene transfer (EL4pIL-2). This effect is mediated by activated natural killer (NK) cells, since we observed the same effect in nude mice but not in NK-depleted mice. Additionally, in mice repeatedly vaccinated with irradiated EL4pIL-2 cells, we observed immunity to challenge with a tumorigenic dose of EL4 cells transfected with a control vector, EL4p. EL4-specific cytotoxic T-lymphocytes (CTLs) were detected in these mice. Mice vaccinated with irradiated EL4p cells were less protected against challenge with a tumorigenic dose of EL4p cells. This study indicates that although some IL-2-producing autologous tumor cells elicit NK-mediated responses and not CTL responses upon inoculation, tumor-specific CTL responses are generated upon repeated vaccinations with these cells. This strategy has potential application for treating a wide variety of cancer patients with autologous IL-2 producing tumor cells.
Similar articles
-
Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.Cancer Res. 2000 Sep 1;60(17):4838-44. Cancer Res. 2000. PMID: 10987295
-
Interleukin 2-induced proliferation of murine natural killer cells in vivo.J Exp Med. 1990 Jan 1;171(1):173-88. doi: 10.1084/jem.171.1.173. J Exp Med. 1990. PMID: 1688606 Free PMC article.
-
Differential effects of myeloid dendritic cells retrovirally transduced to express mammalian or viral interleukin-10 on cytotoxic T lymphocyte and natural killer cell functions and resistance to tumor growth.Transplantation. 2001 May 15;71(9):1334-40. doi: 10.1097/00007890-200105150-00027. Transplantation. 2001. PMID: 11397973
-
Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.Immunology. 1995 Jun;85(2):338-46. Immunology. 1995. PMID: 7642226 Free PMC article.
-
Contact-Dependent Killing by Cytotoxic T Lymphocytes Is Insufficient for EL4 Tumor Regression In Vivo.Cancer Res. 2019 Jul 1;79(13):3406-3416. doi: 10.1158/0008-5472.CAN-18-3147. Epub 2019 Apr 30. Cancer Res. 2019. PMID: 31040155
Cited by
-
TYK2 is a key regulator of the surveillance of B lymphoid tumors.J Clin Invest. 2004 Dec;114(11):1650-8. doi: 10.1172/JCI22315. J Clin Invest. 2004. PMID: 15578097 Free PMC article.
-
B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes.J Exp Med. 1996 Mar 1;183(3):791-800. doi: 10.1084/jem.183.3.791. J Exp Med. 1996. PMID: 8642283 Free PMC article.
-
Immunotherapy III: Combinatorial molecular immunotherapy--a synthesis and suggestions.Cancer Metastasis Rev. 1996 Sep;15(3):351-64. doi: 10.1007/BF00046347. Cancer Metastasis Rev. 1996. PMID: 9034596 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous